Nimodipina Altan (Nimodipine)

Nimodipine, the active ingredient in Nimodipina Altan, is a calcium channel blocker presented as an injection solution for intravenous use. It is employed to prevent cerebral vasospasm following subarachnoid hemorrhage, helping to reduce the risk of delayed cerebral ischemia in affected patients.

GNH USA supplies Nimodipina Altan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and procurement teams worldwide, ensuring consistent quality and regulatory compliance across global markets. The company adheres to stringent Good Distribution Practice standards and provides dedicated technical support for seamless integration into clinical workflows.

Nimodipine is used to address cerebral vasospasm, a complication of subarachnoid hemorrhage, by improving cerebral blood flow.

- Subarachnoid hemorrhage: prophylaxis of cerebral vasospasm to lower risk of delayed ischemic neurologic deficits. - Aneurysmal SAH: reduction of incidence of secondary cerebral infarction through sustained vasodilation. - Post‑hemorrhagic neurological care: support of cerebral perfusion during the critical 14‑day risk period.

Nimodipine may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hypotension: transient drop in blood pressure, especially with rapid infusion. - Headache: mild to moderate intensity, often resolving with continued therapy. - Nausea: occasional gastrointestinal upset without vomiting. - Flushing: warm sensation and reddening of the skin.

Serious or Rare Side Effects: - Severe hypotension: marked blood pressure decline requiring medical intervention. - Myocardial infarction: rare occurrence of cardiac ischemia. - Hepatic dysfunction: elevated liver enzymes indicating liver injury. - Anaphylactic reaction: acute allergic response with rash, bronchospasm or shock.

When using Nimodipine, clinicians should observe specific precautions to minimize risk and ensure safe administration. - Renal impairment: monitor renal function and adjust infusion rate if necessary. - Hepatic impairment: use with caution; liver dysfunction may increase drug exposure. - Concomitant vasodilators: assess for additive hypotensive effects. - Pregnancy: avoid unless the potential benefit justifies the potential risk to the fetus. - Elderly patients: observe closely for exaggerated hypotension and dizziness. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Nimodipine can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other calcium channel blockers: additive vasodilatory effect may cause severe hypotension. - Beta‑blockers: combined use can lead to profound bradycardia and hypotension. - Nitrates: concurrent administration may result in excessive vasodilation and low blood pressure.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase plasma concentrations of Nimodipine. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): reduce Nimodipine levels, potentially diminishing therapeutic effect.